ASND - Ascendis Pharma A/S

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
66.88
+0.63 (+0.95%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close66.25
Open66.65
Bid0.00 x 1400
Ask0.00 x 1100
Day's Range66.33 - 67.69
52 Week Range31.56 - 76.99
Volume169,656
Avg. Volume113,643
Market Cap2.798B
Beta (3Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents25 days ago

    Edited Transcript of ASND earnings conference call or presentation 29-Aug-18 8:30pm GMT

    Q2 2018 Ascendis Pharma A/S Earnings Call

  • TransCon Tech Is a Major Growth Driver for Ascendis Pharma A/S
    Market Realist27 days ago

    TransCon Tech Is a Major Growth Driver for Ascendis Pharma A/S

    Ascendis Pharma A/S (ASND) is a biopharmaceutical company focused on becoming a leading player in the endocrinology rare disease space by leveraging its TransCon technology to develop multiple prodrug therapies. The 12-month consensus analyst recommendation for Ascendis Pharma A/S on September 23 is a “strong buy.” The 12-month consensus target price for the company is $79, which is 18.80% higher than its last closing price on September 21. Ascendis Pharma A/S closed at $66.50 on September 21, 139.73% higher than its 52-week low of $27.74 and 13.63% lower than its 52-week high of $76.99.

  • Ascendis Pharma (ASND) Q2 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Ascendis Pharma (ASND) Q2 2018 Earnings Conference Call Transcript

    ASND earnings call for the period ending June 30, 2018.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of ASND earnings conference call or presentation 30-May-18 8:30pm GMT

    Q1 2018 Ascendis Pharma A/S Earnings Call

  • Five Stocks To Buy According To Top Biotech-Focused Funds
    Insider Monkey6 months ago

    Five Stocks To Buy According To Top Biotech-Focused Funds

    Biotechnology is a very interesting industry to invest in, but also very complex. If you are looking for stocks that are most likely to see their value surge, then your best bet would be to start with biotech companies. The industry focuses on development of novel therapies and drugs that can treat various conditions, therefore […]

  • Reuters6 months ago

    High-profile investors bet on stocks tied to millennials - Sohn Conference

    Hedge fund managers at the high-profile 2018 Sohn Investment Conference in New York pitched stock ideas on Monday that they said should benefit from the growing clout of the millennial generation, ranging from online food ordering to homebuilders. John Khoury, founder and managing partner of the $2.7 billion (£1.94 billion) Long Pond Capital hedge fund, revealed a long position in U.S. homebuilder D.R. Horton Inc (DHI.N), which he said should rise as more millennials age into the first-time home buyer market.

  • Reuters6 months ago

    High-profile investors bet on stocks tied to millennials - Sohn Conference

    Hedge fund managers at the high-profile 2018 Sohn Investment Conference in New York pitched stock ideas on Monday that they said should benefit from the growing clout of the millennial generation, ranging from online food ordering to homebuilders. John Khoury, founder and managing partner of the $2.7 billion (£1.94 billion) Long Pond Capital hedge fund, revealed a long position in U.S. homebuilder D.R. Horton Inc (DHI.N), which he said should rise as more millennials age into the first-time home buyer market.

  • CNBC6 months ago

    Here are the stock picks from the rising hedge fund stars at Sohn

    The Sohn Investment Conference in New York kicked off Monday with hedge fund managers' picks moving markets. Sohn is the most widely anticipated hedge fund event of the year, where managers volunteer their time and best investment ideas to raise money in the fight against childhood cancer. This year, the conference began with Next Wave Sohn, featuring the "next generation of talent" among hedge fund managers.

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of ASND earnings conference call or presentation 28-Mar-18 8:30pm GMT

    Full Year 2017 Ascendis Pharma A/S Earnings Call

  • Ascendis Pharma A/S :ASND-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
    Capital Cube10 months ago

    Ascendis Pharma A/S :ASND-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017

    Categories: Yahoo FinanceGet free summary analysis Ascendis Pharma A/S reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Ascendis Pharma A/S – Advaxis, Inc., Affimed N.V. and Agenus Inc. (ADXS-US, AFMD-US and AGEN-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD ... Read more (Read more...)

  • Thomson Reuters StreetEvents11 months ago

    Edited Transcript of ASND earnings conference call or presentation 16-Nov-17 9:30pm GMT

    Q3 2017 Ascendis Pharma A/S Earnings Call